Multi-million dollar funding round accelerates MI:RNA mission to improve global veterinary diagnostics
12.10.25
Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market
6.30.25
Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement
4.1.25
AbbVie Completes Acquisition of Cerevel Therapeutics
8.1.24
Veterinary Diagnostics Company MI:RNA Raises $4 million Series A Funding
7.9.24
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
11.7.22
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest Capital Management to support continued development of the company’s antibody-cleaving enzyme technology platform across multiple therapeutic areas while extending the expected cash runway through 2024
7.18.22
TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry
5.25.22
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
5.4.22
FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
4.28.22